Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triumph-02: GLS-012 + zimberelimab in advanced non-small cell lung cancer
CTR20232200Phase 2Active
- Sponsor
- Guangzhou Gloria Biosciences Co., Ltd.
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of brivestobart, zimberelimab in non-small cell lung cancer (NSCLC), sponsored by Guangzhou Gloria Biosciences Co., Ltd.. Started Dec 2023; status: active.
02
Drugs
brivestobartzimberelimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20232200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232200.